| 0.7129 0.01 (1.43%) | 10-08 14:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.04  |
1-year : | 1.21 |
| Resists | First : | 0.89 |
Second : | 1.03 |
| Pivot price | 0.71 |
|||
| Supports | First : | 0.65 | Second : | 0.54 |
| MAs | MA(5) : | 0.69  |
MA(20) : | 0.76 |
| MA(100) : | 1 |
MA(250) : | 1.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.8 |
D(3) : | 16.8 |
| RSI | RSI(14): 33 |
|||
| 52-week | High : | 2.09 | Low : | 0.65 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OPTN ] has closed above bottom band by 44.7%. Bollinger Bands are 27.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.74 - 0.74 | 0.74 - 0.74 |
| Low: | 0.68 - 0.69 | 0.69 - 0.69 |
| Close: | 0.7 - 0.7 | 0.7 - 0.71 |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Mon, 07 Oct 2024
Optinose Appoints Terry Kohler as Chief Financial Officer - StockTitan
Tue, 01 Oct 2024
Stonepine Capital Management LLC Invests $2.44 Million in OptiNose, Inc. (NASDAQ:OPTN) - MarketBeat
Fri, 27 Sep 2024
Slammed 34% OptiNose, Inc. (NASDAQ:OPTN) Screens Well Here But There Might Be A Catch - Simply Wall St
Mon, 23 Sep 2024
Loss-Making OptiNose, Inc. (NASDAQ:OPTN) Expected To Breakeven In The Medium-Term - Simply Wall St
Wed, 18 Sep 2024
Optinose CEO sells over $4,000 in company stock - Investing.com
Fri, 13 Sep 2024
OptiNose (NASDAQ:OPTN) shareholders have endured a 88% loss from investing in the stock five years ago - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 151 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 5.8 (%) |
| Held by Institutions | 76.9 (%) |
| Shares Short | 6,960 (K) |
| Shares Short P.Month | 6,960 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.29 |
| Profit Margin | -54.5 % |
| Operating Margin | -32 % |
| Return on Assets (ttm) | -9.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 5.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.49 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -2.08 |
| PEG Ratio | -0.1 |
| Price to Book value | -2.44 |
| Price to Sales | 1.41 |
| Price to Cash Flow | -3.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|